Navigation Links
EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
Date:9/22/2008

AMSTERDAM, September 22 /PRNewswire/ -- Kiadis Pharma announced today that its lead product ATIR(TM) has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation.

"Following the orphan drug designation granted by the FDA for our lead product ATIR(TM), this is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The EMEA's orphan drug designation is reserved for new therapies being developed to treat life-threatening or chronically debilitating diseases or conditions that are relatively rare in the European Union and for which no satisfactory therapy is available. The orphan drug designation provides for incentives to support research and development, exemption from user fees and a ten-year period of market exclusivity in the European Union after product approval.

For the complete press release please go to: http://www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit '/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 2014 ... Sulphate Industry” is a professional and in-depth research ... introduces Potassium Sulphate basic information, including its ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:7/24/2014)... 1000 balances – 4 steps – ... weighing needs and expertly narrows down the mass of ... or even terminals. , First, select the working ... select readability instead) and define the accuracy – it’s ... narrows down the list to models that fit best ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... BIRMINGHAM, Ala., Oct. 31 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... quarter ended September 30, 2008., Third Quarter ... ended September 30, 2008, the Company reported,collaborative and ... to $20.5 million for the three months ended ...
... and waves erode billions of tons of soil from ... plagued with excessive amounts of suspended sediment. According to ... the largest nonpoint source pollution in the environment. , ... obvious wind, water and wave forces breaking apart particles ...
... 30 AVAX Technologies, Inc.,(OTC Bulletin Board: AVXT) ... it closed a bridge loan financing pursuant to ... by the Amendment to Convertible,Note and Warrant Purchase ... Company sold convertible promissory notes,(the "Notes") in the ...
Cached Biology Technology:BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 9Virginia Tech engineers identify conditions that initiate erosion 2Virginia Tech engineers identify conditions that initiate erosion 3AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing 2
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... of native animal species for food or commercial food ... factor in the decline of many species of primates ... that more than half of the species being consumed ... "By surveying not only the meat made available for ... the forest by hunters and brought to villages for ...
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Creating sustainable STEM teacher preparation programs 2
... drug for cocaine addiction and overdose, Journal of the ... what they term the most powerful substance ever discovered for ... to the world,s first effective medicine for fighting overdoses and ... the Sept. 24 issue of the Journal of the ...
... A researcher at Oregon State University has used ... to identify counties in Oregon with high numbers of ... in fighting the illegal drug. The study, presented ... from four sources then identified five counties with the ...
... a muscle fiber mesh at the neuromuscular junction. New work ... Cell Biology reveals that an extracellular matrix protein called ... fit together type="rel"doi="10.1083/jcb.2008. , A neuromuscular junction, or synapse, in ... nerve terminal meeting a flat, oval structure on the muscle ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Sept. 10, 2008 2American Chemical Society's Weekly PressPac -- Sept. 10, 2008 3American Chemical Society's Weekly PressPac -- Sept. 10, 2008 4American Chemical Society's Weekly PressPac -- Sept. 10, 2008 5American Chemical Society's Weekly PressPac -- Sept. 10, 2008 6American Chemical Society's Weekly PressPac -- Sept. 10, 2008 7American Chemical Society's Weekly PressPac -- Sept. 10, 2008 8New method identifies meth hot spots 2New method identifies meth hot spots 3
...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: